FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Kenneth Johnson

Research Profile

Disorders

Living Beings

Anatomy

Brain

Chemicals & Drugs

Phenomena

Procedures

Double-Blind Method

Co-author Network

Publications

TOP 3
Merrikay Oleen-Burkey; Maureen J Lage; Jane Castelli-Haley; Kenneth P Johnson
Burden of a multiple sclerosis relapse: the patient's perspective.
Kenneth P Johnson
Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update.
Kenneth P Johnson; Deborah L Due
Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Kenneth Johnson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Merrikay Oleen-Burkey; Maureen J Lage; Jane Castelli-Haley; Kenneth P Johnson
Burden of a multiple sclerosis relapse: the patient's perspective.
The patient 2012;5(1):57-69.
2010: Kenneth P Johnson
Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update.
Expert opinion on drug metabolism & toxicology 2010;6(5):643-60.
2009: Kenneth P Johnson; Deborah L Due
Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
Expert review of pharmacoeconomics & outcomes research 2009;9(3):205-14.
2009: Jane Castelli-Haley; MerriKay A Oleen-Burkey; Maureen J Lage; Kenneth P Johnson
Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis.
Advances in therapy 2009;26(5):552-62.
2008: Jane Castelli-Haley; MerriKay Oleen-Burkey; Merry-Kay A Oleen-Burkey; Maureen J Lage; Kenneth P Johnson
Glatiramer acetate versus interferon beta-1a for subcutaneous administration: comparison of outcomes among multiple sclerosis patients.
Advances in therapy 2008;25(7):658-73.
2007: Kenneth P Johnson
Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
The neurologist 2007;13(4):182-7.
2007: R M Valenzuela; Kathleen Costello; Man Chen; Areen Said; Kenneth P Johnson; Suhayl Dhib-Jalbut
Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2007;13(6):754-62.
2007: Kenneth P Johnson
Control of multiple sclerosis relapses with immunomodulating agents.
Journal of the neurological sciences 2007;256 Suppl 1():S23-8.
2007: Patricia K Coyle; Kenneth P Johnson
Relapses matter: the costs & consequences of multiple sclerosis relapses.
Journal of the neurological sciences 2007;256 Suppl 1():S1-4.
2007: Steven R Schwid; Andrew D Goodman; Amy Weinstein; Michael P McDermott; Kenneth P Johnson
Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.
Journal of the neurological sciences 2007;255(1-2):57-63.
2007: Christopher Bell; Jonathan Graham; Stephanie Earnshaw; Merrikay Oleen-Burkey; Jane Castelli-Haley; Kenneth P Johnson
Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
Journal of managed care pharmacy : JMCP 2007;13(3):245-61.
2007: Jerry Wolinsky; Ponnada A Narayana; Paul O'Connor; Patricia K Coyle; Corey Ford; Kenneth P Johnson; Aaron Miller; Lillian Pardo; Shaul Kadosh; David Ladkani
Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial.
Annals of neurology 2007;61(1):14-24.
2006: Jai Perumal; Massimo Filippi; Corey Ford; Kenneth P Johnson; Robert P Lisak; Luanne Metz; Alexandros Tselis; Mark Tullman; OA Khan
Glatiramer acetate therapy for multiple sclerosis: a review.
Expert opinion on drug metabolism & toxicology 2006;2(6):1019-29.
2006: Lloyd H Kasper; Daniel E Everitt; Thomas P Leist; Kathleen A Ryan; Mary Ann Mascelli; Kenneth P Johnson; Aparna Raychaudhuri; Tim Vollmer
A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis.
Current medical research and opinion 2006;22(9):1671-8.
2006: CC Ford; Kenneth P Johnson; Robert P Lisak; Hillel Panitch; G Shifronis; Jerry Wolinsky
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients.
Multiple sclerosis (Houndmills, Basingstoke, England) 2006;12(3):309-20.
2005: Kenneth P Johnson; CC Ford; Robert P Lisak; Jerry Wolinsky
Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data.
Acta neurologica Scandinavica 2005;111(1):42-7.
2003: Kenneth P Johnson; BR Brooks; CC Ford; Andrew D Goodman; Robert P Lisak; LW Myers; A A Pruitt; M A Rizzo; JW Rose; LP Weiner; Jerry Wolinsky
Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial.
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(6):585-91.
2003: Filippo Martinelli Boneschi; Marco Rovaris; Kenneth P Johnson; Aaron Miller; Jerry Wolinsky; David Ladkani; Galia Shifroni; Giancarlo Comi; Massimo Filippi
Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.
Multiple sclerosis (Houndmills, Basingstoke, England) 2003;9(4):349-55.
2003: Suhayl Dhib-Jalbut; Man Chen; Areen Said; Min Zhan; Kenneth P Johnson; Roland Martin
Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a Th2-biased phenotype.
Journal of neuroimmunology 2003;140(1-2):163-71.
2002: Man Chen; K Conway; Kenneth P Johnson; Roland Martin; Suhayl Dhib-Jalbut
Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years.
Journal of the neurological sciences 2002;201(1-2):71-7.
2002: Kenneth P Johnson; Lance D Blumhardt
Practical issues in the management of multiple sclerosis. Introduction.
Neurology 2002;58(8 Suppl 4):S1-2.
2001: Kenneth P Johnson; BR Brooks; JA Cohen; CC Ford; J Goldstein; Robert P Lisak; LW Myers; Hillel Panitch; JW Rose; Randolph B Schiffer; T Vollmer; LP Weiner; Jerry Wolinsky
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article].
Neurology 2001;57(12 Suppl 5):S46-53.
2001: Kenneth P Johnson; BR Brooks; JA Cohen; CC Ford; J Goldstein; Robert P Lisak; LW Myers; Hillel Panitch; JW Rose; Randolph B Schiffer; T Vollmer; LP Weiner; Jerry Wolinsky
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. 1995.
Neurology 2001;57(12 Suppl 5):S16-24.
2001: Man Chen; Bruno Gran; Kathleen Costello; Kenneth P Johnson; Roland Martin; Suhayl Dhib-Jalbut
Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.
Multiple sclerosis (Houndmills, Basingstoke, England) 2001;7(4):209-19.
2001: Kenneth P Johnson; J R Baringer
Current therapy of multiple sclerosis.
Hospital practice (1995) 2001;36(4):21-2, 25-8; discussion 28-9.
2001: Jerry Wolinsky; Ponnada A Narayana; Kenneth P Johnson
United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
Multiple sclerosis (Houndmills, Basingstoke, England) 2001;7(1):33-41.
2000: Kenneth P Johnson; BR Brooks; CC Ford; A Goodman; J Guarnaccia; Robert P Lisak; LW Myers; Hillel Panitch; A Pruitt; JW Rose; N Kachuck; Jerry Wolinsky
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
Multiple sclerosis (Houndmills, Basingstoke, England) 2000;6(4):255-66.
1999: DS Goodin; George C Ebers; Kenneth P Johnson; M Rodriguez; William A Sibley; Jerry Wolinsky
The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Neurology 1999;52(9):1737-45.
1999: H Jiang; Bibiana Bielekova; H Okazaki; K Clarence-Smith; Kenneth P Johnson; Gregory K Bergey; Roland Martin; Suhayl Dhib-Jalbut
The effect of vesnarinone on TNF alpha production in human peripheral blood mononuclear cells and microglia: a preclinical study for the treatment of multiple sclerosis.
Journal of neuroimmunology 1999;97(1-2):134-45.
1999: Kenneth P Johnson; Hillel Panitch
Interferon beta treatment for multiple sclerosis.
Lancet 1999;353(9151):494; author reply 497-8.
1998: Kenneth P Johnson; BR Brooks; JA Cohen; CC Ford; J Goldstein; Robert P Lisak; LW Myers; Hillel Panitch; JW Rose; Randolph B Schiffer; T Vollmer; LP Weiner; Jerry Wolinsky
Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
Neurology 1998;50(3):701-8.
1997: Kenneth P Johnson
The historical development of interferons as multiple sclerosis therapies.
Journal of molecular medicine (Berlin, Germany) 1997;75(2):89-94.
1997: Kenneth P Johnson
Role of interferons in demyelinating disease.
Journal of neural transmission. Supplementum 1997;49():111-5.
1996: Christopher Bever Jr; P A Anderson; James L Leslie; Hillel Panitch; Suhayl Dhib-Jalbut; OA Khan; Ron Milo; J Richard Hebel; K L Conway; E Katz; Kenneth P Johnson
Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial.
Neurology 1996;47(6):1457-62.
1996: Kenneth P Johnson
Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone).
Multiple sclerosis (Houndmills, Basingstoke, England) 1996;1(6):325-6.
1996: OA Khan; Q Xia; Christopher Bever Jr; Kenneth P Johnson; Hillel Panitch; Suhayl Dhib-Jalbut
Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration.
Neurology 1996;46(6):1639-43.
1996: Kenneth P Johnson
A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data.
Journal of neurology 1996;243(4 Suppl 1):S3-7.
1996: Suhayl Dhib-Jalbut; H Jiang; Q Xia; L Blatt; Kenneth P Johnson; D Hilt
Comparative effects of interferon-consensus 1, interferon-alpha 2a, and interferon-beta 1b on HLA expression and lymphoproliferation: a preclinical model for treatment of multiple sclerosis.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1996;16(3):195-200.
1995: Christopher Bever Jr; Lynn M Grattan; Hillel Panitch; Kenneth P Johnson
The Brief Repeatable Battery of Neuropsychological Tests for Multiple Sclerosis: a preliminary serial study.
Multiple sclerosis (Houndmills, Basingstoke, England) 1995;1(3):165-9.
1995: H Jiang; Ron Milo; P Swoveland; Kenneth P Johnson; Hillel Panitch; Suhayl Dhib-Jalbut
Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells.
Journal of neuroimmunology 1995;61(1):17-25.
1995: Kenneth P Johnson; B R Brooks; J A Cohen; C C Ford; J Goldstein; Robert P Lisak; L W Myers; Hillel Panitch; J W Rose; Randolph B Schiffer
Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.
Neurology 1995;45(7):1268-76.
1994: L Jacobs; Kenneth P Johnson
A brief history of the use of interferons as treatment of multiple sclerosis.
Archives of neurology 1994;51(12):1245-52.
1994: Christopher Bever Jr; Hillel Panitch; Kenneth P Johnson
Increased cathepsin B activity in peripheral blood mononuclear cells of multiple sclerosis patients.
Neurology 1994;44(4):745-8.
1994: Kenneth P Johnson
Experimental therapy of relapsing-remitting multiple sclerosis with copolymer-1.
Annals of neurology 1994;36 Suppl():S115-7.
1993: RL Knobler; J I Greenstein; Kenneth P Johnson; Fred D Lublin; Hillel Panitch; K Conway; S V Grant-Gorsen; J Muldoon; S G Marcus; J C Wallenberg
Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.
Journal of interferon research 1993;13(5):333-40.
1992: R Burgerman; D Rigamonti; J M Randle; Paul S Fishman; Hillel Panitch; Kenneth P Johnson
The association of cervical spondylosis and multiple sclerosis.
Surgical neurology 1992;38(4):265-70.
1992: Kenneth P Johnson; Hillel Panitch
Interferon therapy for multiple sclerosis.
Maryland medical journal (Baltimore, Md. : 1985) 1992;41(7):601-3.
1991: Christopher Bever Jr; Hillel Panitch; H B Levy; D E McFarlin; Kenneth P Johnson
Gamma-interferon induction in patients with chronic progressive MS.
Neurology 1991;41(7):1124-7.
1990: Christopher Bever Jr; James L Leslie; D L Camenga; Hillel Panitch; Kenneth P Johnson
Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis.
Annals of neurology 1990;27(4):421-7.
1989: P T Swoveland; Kenneth P Johnson
Host age and cell type influence measles virus protein expression in the central nervous system.
Virology 1989;170(1):131-8.
1989: Kenneth P Johnson; Hillel Panitch
Effects of experimental recombinant interferons on multiple sclerosis.
Transactions of the American Clinical and Climatological Association 1989;100():171-6.
1988: Kenneth P Johnson
Treatment of multiple sclerosis with various interferons: the cons.
Neurology 1988;38(7 Suppl 2):62-5.
1988: Robert L Hirsch; Kenneth P Johnson; D L Camenga
The placebo effect during a double blind trial of recombinant alpha 2 interferon in multiple sclerosis patients: immunological and clinical findings.
The International journal of neuroscience 1988;39(3-4):189-96.
1987: Hillel Panitch; Robert L Hirsch; J Schindler; Kenneth P Johnson
Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system.
Neurology 1987;37(7):1097-102.
1987: Hillel Panitch; Robert L Hirsch; A S Haley; Kenneth P Johnson
Exacerbations of multiple sclerosis in patients treated with gamma interferon.
Lancet 1987;1(8538):893-5.
1987: D A Drubach; Hillel Panitch; Kenneth P Johnson
Viral and immune-mediated factors in the pathogenesis of psychiatric disease.
The Hillside journal of clinical psychiatry 1987;9(2):163-83.
1986: D L Camenga; Kenneth P Johnson; M Alter; C D Engelhardt; Paul S Fishman; J I Greenstein; A S Haley; Robert L Hirsch; J E Kleiner; V Y Kofie
Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis.
Archives of neurology 1986;43(12):1239-46.
1986: Robert L Hirsch; Kenneth P Johnson
The effects of long-term administration of recombinant alpha-2 interferon on lymphocyte subsets, proliferation, and suppressor cell function in multiple sclerosis.
Journal of interferon research 1986;6(2):171-7.
1985: Robert L Hirsch; Hillel Panitch; Kenneth P Johnson
Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro.
Journal of clinical immunology 1985;5(6):386-9.
1985: Robert L Hirsch; Kenneth P Johnson
Natural killer cell activity in multiple sclerosis patients treated with recombinant interferon-alpha 2.
Clinical immunology and immunopathology 1985;37(2):236-44.
1985: Robert L Hirsch; J Ordonez; Hillel Panitch; Kenneth P Johnson
T8 antigen density on peripheral blood lymphocytes remains unchanged during exacerbations of multiple sclerosis.
Journal of neuroimmunology 1985;9(6):391-8.
1985: Hillel Panitch; G S Francis; C J Hooper; T C Merigan; Kenneth P Johnson
Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon.
Annals of neurology 1985;18(4):434-8.
1985: Roberta Kamin-Lewis; Hillel Panitch; Kenneth P Johnson
Leukocytes from multiple sclerosis patients respond to alpha- and gamma-interferons.
Journal of neuroimmunology 1985;9(3-4):221-7.
1985: Robert L Hirsch; Kenneth P Johnson
The effect of recombinant alpha 2-interferon on defective natural killer cell activity in multiple sclerosis.
Neurology 1985;35(4):597-600.
1984: R L Knobler; Hillel Panitch; S L Braheny; J C Sipe; G P Rice; J R Huddlestone; G S Francis; C K Hooper; Roberta Kamin-Lewis; Kenneth P Johnson
Systemic alpha-interferon therapy of multiple sclerosis.
Neurology 1984;34(10):1273-9.
1984: Kenneth P Johnson; P T Swoveland
Rabies.
Neurologic clinics 1984;2(2):255-65.
1984: R L Knobler; Hillel Panitch; S L Braheny; J C Sipe; G P Rice; J R Huddlestone; G S Francis; C J Hooper; Roberta Kamin-Lewis; Kenneth P Johnson
Clinical trial of natural alpha interferon in multiple sclerosis.
Annals of the New York Academy of Sciences 1984;436():382-8.
1984: Roberta Kamin-Lewis; Hillel Panitch; T C Merigan; Kenneth P Johnson
Decreased interferon synthesis and responsiveness to interferon by leukocytes from multiple sclerosis patients given natural alpha interferon.
Journal of interferon research 1984;4(3):423-32.
1983: Kenneth P Johnson
Systemic interferon therapy for multiple sclerosis. Design of a trial.
Archives of neurology 1983;40(11):681-2.
1983: C M Poser; D W Paty; L Scheinberg; W I McDonald; F A Davis; G C Ebers; Kenneth P Johnson; W A Sibley; D H Silberberg; W W Tourtellotte
New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Annals of neurology 1983;13(3):227-31.
1983: P T Swoveland; Kenneth P Johnson
Identification of rabies antigen in human and animal tissues.
Annals of the New York Academy of Sciences 1983;420():185-91.
1982: Leslie Tobler; Kenneth P Johnson; G Case Buehring
Measles- or mumps virus-infected cells forming rosettes with lymphocytes from patients with multiple sclerosis.
Archives of neurology 1982;39(9):565-9.
1982: Leslie Tobler; Kenneth P Johnson; G C Buehring
Immune response of hamsters to experimental central nervous system infection with measles virus.
Journal of neuroimmunology 1982;2(3-4):307-20.
1982: E Norrby; S N Chen; T Togashi; H Shesberadaran; Kenneth P Johnson
Five measles virus antigens demonstrated by use of mouse hybridoma antibodies in productively infected tissue culture cells.
Archives of virology 1982;71(1):1-11.
1982: Kenneth P Johnson; E Norrby; P Swoveland; D R Carrigan
Expression of five viral antigens in cells infected with wild-type and SSPE strains of measles virus: correlation with cytopathic effects and productivity of infections.
Archives of virology 1982;73(3-4):255-62.
1981: R R McKendall; D R Carrigan; Kenneth P Johnson
Lymphoid cell infection by measles virus in newborn hamsters. Role for monocytes in virus spread to distant sites.
Journal of neuroimmunology 1981;1(3):261-74.
1981: D R Carrigan; Kenneth P Johnson
A mathematical model for the hemolysin of measles virus.
Journal of virological methods 1981;3(2):71-81.
1981: Kenneth P Johnson; E Norrby; P Swoveland; D R Carrigan
Experimental subacute sclerosing panencephalitis: selective disappearance of measles virus matrix protein from the Central nervous system.
The Journal of infectious diseases 1981;144(2):161-9.
1981: Ashley T Haase; P Swoveland; L Stowring; P Ventura; Kenneth P Johnson; E Norrby; C J Gibbs
Measles virus genome in infections of the central nervous system.
The Journal of infectious diseases 1981;144(2):154-60.
1981: I M Parhad; Kenneth P Johnson; Jerry Wolinsky; P Swoveland
Encephalitis after inhalation of measles virus: a pathogenetic study in hamsters.
Annals of neurology 1981;9(1):21-7.
1981: Z Z Hosein; Kenneth P Johnson
Isoelectric focusing of cerebrospinal fluid proteins in the diagnosis of multiple sclerosis.
Neurology 1981;31(1):70-6.
1981: Kenneth P Johnson
Experimental subacute sclerosing panencephalitis (SSPE) in the hamster.
Advances in experimental medicine and biology 1981;134():303-9.
1980: R L Owen; P C Dau; Kenneth P Johnson; L E Spitler
Immunologic mechanisms in multiple sclerosis. Exacerbation by type A hepatitis and skin test antigens.
JAMA : the journal of the American Medical Association 1980;244(20):2307-9.
1980: P C Dau; J H Petajan; Kenneth P Johnson; Hillel Panitch; M B Bornstein
Plasmapheresis in multiple sclerosis: preliminary findings.
Neurology 1980;30(10):1023-8.
1980: B Forghani; N E Cremer; Kenneth P Johnson; G Fein; W H Likosky
Comprehensive viral immunology of multiple sclerosis. III. Analysis of CSF antibodies by radioimmunoassay.
Archives of neurology 1980;37(10):616-9.
1980: N E Cremer; Kenneth P Johnson; G Fein; W H Likosky
Comprehensive viral immunology of multiple sclerosis. II. Analysis of serum and CSF antibodies by standard serologic methods.
Archives of neurology 1980;37(10):610-5.
1980: Kenneth P Johnson; W H Likosky; B J Nelson; G Fein
Comprehensive viral immunology of multiple sclerosis. I. Clinical, epidemiological, and CSF studies.
Archives of neurology 1980;37(9):537-41.
1980: Kenneth P Johnson
Multiple sclerosis and the immune system.
Archives of neurology 1980;37(9):535-6.
1980: Kenneth P Johnson; P T Swoveland; R W Emmons
Diagnosis of rabies by immunofluorescence in trypsin-treated histologic sections.
JAMA : the journal of the American Medical Association 1980;244(1):41-3.
1980: I M Parhad; Kenneth P Johnson; Jerry Wolinsky; P Swoveland
Measles retinopathy. A hamster model of acute and chronic lesions.
Laboratory investigation; a journal of technical methods and pathology 1980;43(1):52-60.
1980: D R Carrigan; Kenneth P Johnson
Chronic, relapsing myelitis in hamsters associated with experimental measles virus infection.
Proceedings of the National Academy of Sciences of the United States of America 1980;77(7):4297-300.
1980: Kenneth P Johnson
Cerebrospinal fluid and blood assays of diagnostic usefulness in multiple sclerosis.
Neurology 1980;30(7 Pt 2):106-9.
1980: Hillel Panitch; C J Hooper; Kenneth P Johnson
CSF antibody to myelin basic protein. Measurement in patients with multiple sclerosis and subacute sclerosing panencephalitis.
Archives of neurology 1980;37(4):206-9.
1980: E Norrby; P Swoveland; K Kristensson; Kenneth P Johnson
Further studies on subacute encephalitis and hydrocephalus in hamsters caused by measles virus from persistently infected cell cultures.
Journal of medical virology 1980;5(2):109-16.
1980: S M Stahl; Kenneth P Johnson; N Malamud
The clinical and pathological spectrum of brain-stem vascular malformations. Long-term course stimulates multiple sclerosis.
Archives of neurology 1980;37(1):25-9.
1979: P T Swoveland; Kenneth P Johnson
Enhancement of fluorescent antibody staining of viral antigens in formalin-fixed tissues by trypsin digestion.
The Journal of infectious diseases 1979;140(5):758-64.
1979: N E Cremer; Kenneth P Johnson; G Fein; W H Likosky
Cytotoxic antibody to cells infected with measles virus in serum and cerebrospinal fluid of multiple sclerosis and control patients.
Journal of clinical microbiology 1979;9(6):716-21.
1979: Kenneth P Johnson; W S Connor
Guinea pig cytomegalovirus: transplacental transmission. Brief report.
Archives of virology 1979;59(3):263-7.
1978: D C Traviesa; S D Prystowsky; B J Nelson; Kenneth P Johnson
Cerebrospinal fluid findings in asymptomatic patients with reactive serum fluorescent treponemal antibody absorption tests.
Annals of neurology 1978;4(6):524-30.
1978: Kenneth P Johnson
Viral infections of the hamster central nervous system.
Federation proceedings 1978;37(7):2074-5.
1978: D R Carrigan; R R McKendall; Kenneth P Johnson
CNS disease following dissemination of SSPE measles virus from intraperitoneal inoculation of suckling hamsters.
Journal of medical virology 1978;2(4):347-57.
1978: B Forghani; N E Cremer; Kenneth P Johnson; A H Ginsberg; W H Likosky
Viral antibodies in cerebrospinal fluid of multiple sclerosis and control patients: comparison between radioimmunoassay and conventional techniques.
Journal of clinical microbiology 1978;7(1):63-9.
1977: A H Ginsberg; Kenneth P Johnson
The effect of cyclophosphamide on intracerebral vaccinia virus infection in Balb/C mice.
Experimental and molecular pathology 1977;27(3):285-94.
1977: Kenneth P Johnson; P Swoveland
Measles antigen distribution in brains of chronically infected hamsters. An immunoperoxidase study of experimental subacute sclerosing panencephalitis.
Laboratory investigation; a journal of technical methods and pathology 1977;37(5):459-65.
1977: Kenneth P Johnson; B J Nelson
Multiple sclerosis: diagnostic usefulness of cerebrospinal fluid.
Annals of neurology 1977;2(5):425-31.
1977: K H Rand; Kenneth P Johnson; L J Rubinstein; Jerry Wolinsky; J B Penney; D L Walker; B L Padgett; T C Merigan
Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy: use of virus-containing cells in the urine to assess response to therapy.
Annals of neurology 1977;1(5):458-62.
1977: Jerry Wolinsky; P Swoveland; Kenneth P Johnson; J R Baringer
Subacute measles encephalitis complicating Hodgkin's disease in an adult.
Annals of neurology 1977;1(5):452-7.
1977: Kenneth P Johnson; S C Arrigo; B J Nelson; A Ginsberg
Agarose electrophoresis of cerebrospinal fluid in multiple sclerosis. A simplified method for demonstrating cerebrospinal fluid oligoclonal immunoglobulin bands.
Neurology 1977;27(3):273-7.
1977: A H Ginsberg; W T Monte; Kenneth P Johnson
Effect of cyclophosphamide in vitro and on vaccinia virus replication in tissue culture.
Journal of virology 1977;21(1):277-83.
1977: C S Raine; D P Byington; Kenneth P Johnson
Experimental subacute sclerosing panencephalitis in the hamster: ultrastructure of the chronic disease.
Neurología, neurocirugía, psiquiatría 1977;18(2-3 Suppl):539-61.
1977: Kenneth P Johnson; D P Byington; L Gaddis
Virological and immunological studies in experimental SSPE.
Neurología, neurocirugía, psiquiatría 1977;18(2-3 Suppl):495-507.
1977: Kenneth P Johnson; E Norrby
Subacute sclerosing panencephalitis (SSPE) agent in hamsters.
Neurología, neurocirugía, psiquiatría 1977;18(2-3 Suppl):469-83.
1976: P C Dau; Kenneth P Johnson; L E Spitler
The effect of levamisole on cellular immunity in multiple sclerosis.
Clinical and experimental immunology 1976;26(2):302-9.
1976: W S Connor; Kenneth P Johnson
Cytomegalovirus infection in weanling guinea pigs.
The Journal of infectious diseases 1976;134(5):442-9.
1976: A H Ginsberg; Kenneth P Johnson
Vaccinia virus meningitis in mice after intracerebral inoculation.
Infection and immunity 1976;13(4):1221-7.
1976: Jerry Wolinsky; Kenneth P Johnson; K Rand; T C Merigan
Progressive multifocal leukoencephalopathy: clinical pathological correlates and failure of a drug trial in two patients.
Transactions of the American Neurological Association 1976;101():81-2.
1975: Kenneth P Johnson; E G Feldman; D P Byington
Effect of neonatal thymectomy on experimental subacute sclerosing panencephalitis in adult hamsters.
Infection and immunity 1975;12(6):1464-9.
1975: C S Raine; D P Byington; Kenneth P Johnson
Subacute sclerosing panencephalitis in the hamster. Ultrastructure of the acute disease in newborns and weanlings.
Laboratory investigation; a journal of technical methods and pathology 1975;33(2):108-16.
1975: D P Byington; Kenneth P Johnson
Subacute sclerosing panencephalitis virus in immunosuppressed adult hamster.
Laboratory investigation; a journal of technical methods and pathology 1975;32(1):91-7.
1974: Kenneth P Johnson; E Norrby
Subacute sclerosing panencephalitis (SSPE) agent in hamsters. 3. Induction of defective measles infection in hamster brain.
Experimental and molecular pathology 1974;21(2):166-78.
1974: C S Raine; D P Byington; Kenneth P Johnson
Experimental subacute sclerosing panencephalitis in the hamster. Ultrastructure of the chronic disease.
Laboratory investigation; a journal of technical methods and pathology 1974;31(4):355-68.
1974: Kenneth P Johnson; L C Ferguson; D P Byington; D R Redman
Multiple fetal malformations due to persistent viral infection. I. Abortion, intrauterine death, and gross abnormalities in fetal swine infected with hog cholera vaccine virus.
Laboratory investigation; a journal of technical methods and pathology 1974;30(5):608-17.
1974: Kenneth P Johnson; D P Byington; L Gaddis
Subacute sclerosing panencephalitis.
Advances in neurology 1974;6():77-86.
1974: Kenneth P Johnson
Viral infections of the developing nervous system.
Advances in neurology 1974;6():53-67.
1973: W R Bauer; A P Turel; Kenneth P Johnson
Progressive multifocal leukoencephalopathy and cytarabine. Remission with treatment.
JAMA : the journal of the American Medical Association 1973;226(2):174-6.
1973: D P Byington; Kenneth P Johnson
Subacute sclerosing panencephalitis (SSPE) agent in hamsters. II. The neuropathology of acute and chronic infections.
Experimental and molecular pathology 1973;18(3):345-56.
1973: D J Novak; Kenneth P Johnson
Relapsing idiopathic polyneuritis during pregnancy. Immunological aspects and literature review.
Archives of neurology 1973;28(4):219-23.
1972: Kenneth P Johnson; M S Rosenthal; P I Lerner
Herpes simplex encephalitis. The course in five virologically proven cases.
Archives of neurology 1972;27(2):103-8.
1972: D P Byington; Kenneth P Johnson
Experimental subacute sclerosing panencephalitis in the hamster: correlation of age with chronic inclusion-cell encephalitis.
The Journal of infectious diseases 1972;126(1):18-26.
1972: Kenneth P Johnson; Richard T Johnson
Granular ependymitis. Occurrence in myxovirus infected rodents and prevalence in man.
The American journal of pathology 1972;67(3):511-26.
1972: M Leyh-Bouille; M Nakel; J M Frère; Kenneth P Johnson; J M Ghuysen; M Nieto; H R Perkins
Penicillin-sensitive DD-carboxypeptidases from Streptomyces strains R39 and K11.
Biochemistry 1972;11(7):1290-8.
1971: Kenneth P Johnson; D P Byington
Subacute sclerosing panencephalitis (SSPE) agent in hamsters. I. Acute giant cell encephalitis in newborn animals.
Experimental and molecular pathology 1971;15(3):373-9.
1971: Kenneth P Johnson; L C Gaddis
Miniculture plaquing technique for mouse cytomegalovirus.
Applied microbiology 1971;22(1):139-40.
1971: Kenneth P Johnson; R Klasnja; Richard T Johnson
Neural tube defects of chick embryos: an indirect result of influenza A virus infection.
Journal of neuropathology and experimental neurology 1971;30(1):68-74.
1970: G D Timmons; Kenneth P Johnson
Aqueductal stenosis and hydrocephalus after mumps encephalitis.
The New England journal of medicine 1970;283(27):1505-7.
1970: Kenneth P Johnson
California encephalitis. Epidemiologic studies in Ohio using a quantitative metabolic inhibition test.
American journal of epidemiology 1970;92(3):203-9.
1969: Kenneth P Johnson
Mouse cytomegalovirus: placental infection.
The Journal of infectious diseases 1969;120(4):445-50.
1969: Richard T Johnson; Kenneth P Johnson
Hydrocephalus as a sequela of experimental myxovirus infections.
Experimental and molecular pathology 1969;10(1):68-80.
1968: Richard T Johnson; Kenneth P Johnson
Hydrocephalus following viral infection: the pathology of aqueductal stenosis developing after experimental mumps virus infection.
Journal of neuropathology and experimental neurology 1968;27(4):591-606.
1968: Kenneth P Johnson; M L Lepow; Richard T Johnson
California encephalitis. I. Clinical and epidemiological studies.
Neurology 1968;18(3):250-4.
1968: Richard T Johnson; Kenneth P Johnson
Myxoviruses and infections of the nervous system.
Neurology 1968;18(1 Pt 2):101-3.
1967: Richard T Johnson; Kenneth P Johnson; C J Edmonds
Virus-induced hydrocephalus: development of aqueductal stenosis in hamsters after mumps infection.
Science (New York, N.Y.) 1967;157(3792):1066-7.